 | • レポートコード：MRC309Z7939 • 出版社/出版日：GlobalInfoResearch / 2023年9月 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| GlobalInfoResearchの最新の調査によると、世界の癌に対するモノクローナル抗体の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。 このレポートは、世界の癌に対するモノクローナル抗体市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。 市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。 本レポートの主な目的は次のとおりです。 - 世界および主要国の市場機会の規模を決定するため - 癌に対するモノクローナル抗体の成長可能性を評価するため - 各製品および最終用途市場の将来の成長を予測するため - 市場に影響を与える競争要因を評価するため 癌に対するモノクローナル抗体市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメント ・リツキシマブ、トラスツズマブ、ベバシズマブ、その他 用途別セグメント ・リンパ腫、非小細胞肺がん（NSCLC）、乳がん、子宮頸がん、その他 主要な市場プレーヤー ・AbbVie、Merck、Roche、Bristol Myers Squibb、Daiichi Sankyo、Johnson & Johnson、Biogen、Novartis、Takeda Pharmaceuticals、Astellas Pharma、Qilu Pharmaceutical、Luye Pharma、Hengrui Pharmaceuticals、Innovent 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、癌に対するモノクローナル抗体製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な癌に対するモノクローナル抗体メーカーの企業概要、2019年～2022年までの癌に対するモノクローナル抗体の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な癌に対するモノクローナル抗体メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2018年～2029年までの地域別癌に対するモノクローナル抗体の販売量、売上、成長性を示しています。 ・第5、6章では、2018年～2029年までの癌に対するモノクローナル抗体の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での癌に対するモノクローナル抗体市場予測を収録しています。 ・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。 ・第13章では、主要な原材料、主要なサプライヤー、および癌に対するモノクローナル抗体の産業チェーンを掲載しています。 ・第14、15章では、癌に対するモノクローナル抗体の販売チャネル、販売業者、顧客、調査結果について説明します。 ***** 目次(一部) ***** ・市場概要 - 癌に対するモノクローナル抗体の概要 - 種類別分析（2018年vs2022年vs2029年）：リツキシマブ、トラスツズマブ、ベバシズマブ、その他 - 用途別分析（2018年vs2022年vs2029年）：リンパ腫、非小細胞肺がん（NSCLC）、乳がん、子宮頸がん、その他 - 世界の癌に対するモノクローナル抗体市場規模・予測 - 世界の癌に対するモノクローナル抗体生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - AbbVie、Merck、Roche、Bristol Myers Squibb、Daiichi Sankyo、Johnson & Johnson、Biogen、Novartis、Takeda Pharmaceuticals、Astellas Pharma、Qilu Pharmaceutical、Luye Pharma、Hengrui Pharmaceuticals、Innovent ・メーカー別市場シェア・市場集中度 ・地域別市場分析2018年-2029年 ・種類別分析2018年-2029年：リツキシマブ、トラスツズマブ、ベバシズマブ、その他 ・用途別分析2018年-2029年：リンパ腫、非小細胞肺がん（NSCLC）、乳がん、子宮頸がん、その他 ・癌に対するモノクローナル抗体の北米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・癌に対するモノクローナル抗体のヨーロッパ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・癌に対するモノクローナル抗体のアジア市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・癌に対するモノクローナル抗体の南米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・癌に対するモノクローナル抗体の中東・アフリカ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析） ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
According to our (Global Info Research) latest study, the global Monoclonal Antibodies for Cancers market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
Monoclonal antibodies (also called moAbs or mAbs) are proteins made in laboratories that act like proteins called antibodies in our bodies At present, monoclonal antibody drugs have become the main treatment drugs for major difficult diseases such as tumors and autoimmune diseases.
The Global Info Research report includes an overview of the development of the Monoclonal Antibodies for Cancers industry chain, the market status of Lymphoma (Rituximab, Trastuzumab), Non-small Cell Lung Cancer (NSCLC) (Rituximab, Trastuzumab), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Monoclonal Antibodies for Cancers.
Regionally, the report analyzes the Monoclonal Antibodies for Cancers markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Monoclonal Antibodies for Cancers market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Monoclonal Antibodies for Cancers market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Monoclonal Antibodies for Cancers industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Rituximab, Trastuzumab).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Monoclonal Antibodies for Cancers market.
Regional Analysis: The report involves examining the Monoclonal Antibodies for Cancers market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Monoclonal Antibodies for Cancers market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Monoclonal Antibodies for Cancers:
Company Analysis: Report covers individual Monoclonal Antibodies for Cancers manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Monoclonal Antibodies for Cancers This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lymphoma, Non-small Cell Lung Cancer (NSCLC)).
Technology Analysis: Report covers specific technologies relevant to Monoclonal Antibodies for Cancers. It assesses the current state, advancements, and potential future developments in Monoclonal Antibodies for Cancers areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Monoclonal Antibodies for Cancers market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Monoclonal Antibodies for Cancers market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Rituximab
Trastuzumab
Bevacizumab
Others
Market segment by Application
Lymphoma
Non-small Cell Lung Cancer (NSCLC)
Breast Cancer
Cervical Cancer
Others
Major players covered
AbbVie
Merck
Roche
Bristol Myers Squibb
Daiichi Sankyo
Johnson & Johnson
Biogen
Novartis
Takeda Pharmaceuticals
Astellas Pharma
Qilu Pharmaceutical
Luye Pharma
Hengrui Pharmaceuticals
Innovent
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Monoclonal Antibodies for Cancers product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Monoclonal Antibodies for Cancers, with price, sales, revenue and global market share of Monoclonal Antibodies for Cancers from 2018 to 2023.
Chapter 3, the Monoclonal Antibodies for Cancers competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Monoclonal Antibodies for Cancers breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Monoclonal Antibodies for Cancers market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Monoclonal Antibodies for Cancers.
Chapter 14 and 15, to describe Monoclonal Antibodies for Cancers sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Monoclonal Antibodies for Cancers
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Monoclonal Antibodies for Cancers Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Rituximab
1.3.3 Trastuzumab
1.3.4 Bevacizumab
1.3.5 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Monoclonal Antibodies for Cancers Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Lymphoma
1.4.3 Non-small Cell Lung Cancer (NSCLC)
1.4.4 Breast Cancer
1.4.5 Cervical Cancer
1.4.6 Others
1.5 Global Monoclonal Antibodies for Cancers Market Size & Forecast
1.5.1 Global Monoclonal Antibodies for Cancers Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Monoclonal Antibodies for Cancers Sales Quantity (2018-2029)
1.5.3 Global Monoclonal Antibodies for Cancers Average Price (2018-2029)
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Monoclonal Antibodies for Cancers Product and Services
2.1.4 AbbVie Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AbbVie Recent Developments/Updates
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business
2.2.3 Merck Monoclonal Antibodies for Cancers Product and Services
2.2.4 Merck Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Merck Recent Developments/Updates
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Monoclonal Antibodies for Cancers Product and Services
2.3.4 Roche Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Roche Recent Developments/Updates
2.4 Bristol Myers Squibb
2.4.1 Bristol Myers Squibb Details
2.4.2 Bristol Myers Squibb Major Business
2.4.3 Bristol Myers Squibb Monoclonal Antibodies for Cancers Product and Services
2.4.4 Bristol Myers Squibb Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Bristol Myers Squibb Recent Developments/Updates
2.5 Daiichi Sankyo
2.5.1 Daiichi Sankyo Details
2.5.2 Daiichi Sankyo Major Business
2.5.3 Daiichi Sankyo Monoclonal Antibodies for Cancers Product and Services
2.5.4 Daiichi Sankyo Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Daiichi Sankyo Recent Developments/Updates
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson Monoclonal Antibodies for Cancers Product and Services
2.6.4 Johnson & Johnson Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Johnson & Johnson Recent Developments/Updates
2.7 Biogen
2.7.1 Biogen Details
2.7.2 Biogen Major Business
2.7.3 Biogen Monoclonal Antibodies for Cancers Product and Services
2.7.4 Biogen Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Biogen Recent Developments/Updates
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Monoclonal Antibodies for Cancers Product and Services
2.8.4 Novartis Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Novartis Recent Developments/Updates
2.9 Takeda Pharmaceuticals
2.9.1 Takeda Pharmaceuticals Details
2.9.2 Takeda Pharmaceuticals Major Business
2.9.3 Takeda Pharmaceuticals Monoclonal Antibodies for Cancers Product and Services
2.9.4 Takeda Pharmaceuticals Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Takeda Pharmaceuticals Recent Developments/Updates
2.10 Astellas Pharma
2.10.1 Astellas Pharma Details
2.10.2 Astellas Pharma Major Business
2.10.3 Astellas Pharma Monoclonal Antibodies for Cancers Product and Services
2.10.4 Astellas Pharma Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Astellas Pharma Recent Developments/Updates
2.11 Qilu Pharmaceutical
2.11.1 Qilu Pharmaceutical Details
2.11.2 Qilu Pharmaceutical Major Business
2.11.3 Qilu Pharmaceutical Monoclonal Antibodies for Cancers Product and Services
2.11.4 Qilu Pharmaceutical Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Qilu Pharmaceutical Recent Developments/Updates
2.12 Luye Pharma
2.12.1 Luye Pharma Details
2.12.2 Luye Pharma Major Business
2.12.3 Luye Pharma Monoclonal Antibodies for Cancers Product and Services
2.12.4 Luye Pharma Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Luye Pharma Recent Developments/Updates
2.13 Hengrui Pharmaceuticals
2.13.1 Hengrui Pharmaceuticals Details
2.13.2 Hengrui Pharmaceuticals Major Business
2.13.3 Hengrui Pharmaceuticals Monoclonal Antibodies for Cancers Product and Services
2.13.4 Hengrui Pharmaceuticals Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Hengrui Pharmaceuticals Recent Developments/Updates
2.14 Innovent
2.14.1 Innovent Details
2.14.2 Innovent Major Business
2.14.3 Innovent Monoclonal Antibodies for Cancers Product and Services
2.14.4 Innovent Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Innovent Recent Developments/Updates
3 Competitive Environment: Monoclonal Antibodies for Cancers by Manufacturer
3.1 Global Monoclonal Antibodies for Cancers Sales Quantity by Manufacturer (2018-2023)
3.2 Global Monoclonal Antibodies for Cancers Revenue by Manufacturer (2018-2023)
3.3 Global Monoclonal Antibodies for Cancers Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Monoclonal Antibodies for Cancers by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Monoclonal Antibodies for Cancers Manufacturer Market Share in 2022
3.4.2 Top 6 Monoclonal Antibodies for Cancers Manufacturer Market Share in 2022
3.5 Monoclonal Antibodies for Cancers Market: Overall Company Footprint Analysis
3.5.1 Monoclonal Antibodies for Cancers Market: Region Footprint
3.5.2 Monoclonal Antibodies for Cancers Market: Company Product Type Footprint
3.5.3 Monoclonal Antibodies for Cancers Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Monoclonal Antibodies for Cancers Market Size by Region
4.1.1 Global Monoclonal Antibodies for Cancers Sales Quantity by Region (2018-2029)
4.1.2 Global Monoclonal Antibodies for Cancers Consumption Value by Region (2018-2029)
4.1.3 Global Monoclonal Antibodies for Cancers Average Price by Region (2018-2029)
4.2 North America Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
4.3 Europe Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
4.4 Asia-Pacific Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
4.5 South America Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
4.6 Middle East and Africa Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
5.2 Global Monoclonal Antibodies for Cancers Consumption Value by Type (2018-2029)
5.3 Global Monoclonal Antibodies for Cancers Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
6.2 Global Monoclonal Antibodies for Cancers Consumption Value by Application (2018-2029)
6.3 Global Monoclonal Antibodies for Cancers Average Price by Application (2018-2029)
7 North America
7.1 North America Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
7.2 North America Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
7.3 North America Monoclonal Antibodies for Cancers Market Size by Country
7.3.1 North America Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2029)
7.3.2 North America Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
8.2 Europe Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
8.3 Europe Monoclonal Antibodies for Cancers Market Size by Country
8.3.1 Europe Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2029)
8.3.2 Europe Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Monoclonal Antibodies for Cancers Market Size by Region
9.3.1 Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Monoclonal Antibodies for Cancers Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
10.2 South America Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
10.3 South America Monoclonal Antibodies for Cancers Market Size by Country
10.3.1 South America Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2029)
10.3.2 South America Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Monoclonal Antibodies for Cancers Market Size by Country
11.3.1 Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Monoclonal Antibodies for Cancers Market Drivers
12.2 Monoclonal Antibodies for Cancers Market Restraints
12.3 Monoclonal Antibodies for Cancers Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Monoclonal Antibodies for Cancers and Key Manufacturers
13.2 Manufacturing Costs Percentage of Monoclonal Antibodies for Cancers
13.3 Monoclonal Antibodies for Cancers Production Process
13.4 Monoclonal Antibodies for Cancers Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Monoclonal Antibodies for Cancers Typical Distributors
14.3 Monoclonal Antibodies for Cancers Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer